Dexcel Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DEXCEL
DEXCEL has seventeen approved drugs.
There are six US patents protecting DEXCEL drugs. There is one tentative approval on DEXCEL drugs.
There are eight patent family members on DEXCEL drugs in four countries and fifty-nine supplementary protection certificates in sixteen countries.
Summary for Dexcel
| International Patents: | 8 |
| US Patents: | 6 |
| Tradenames: | 14 |
| Ingredients: | 14 |
| NDAs: | 17 |
| Patent Litigation for Dexcel: | See patent lawsuits for Dexcel |
Drugs and US Patents for Dexcel
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dexcel | TOFACITINIB CITRATE | tofacitinib citrate | TABLET, EXTENDED RELEASE;ORAL | 218668-001 | Dec 16, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dexcel | VIGABATRIN | vigabatrin | TABLET;ORAL | 215109-001 | Sep 23, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dexcel Pharma | OMEPRAZOLE | omeprazole | TABLET, DELAYED RELEASE;ORAL | 022032-001 | Dec 4, 2007 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Dexcel | PANTOPRAZOLE SODIUM | pantoprazole sodium | FOR SUSPENSION, DELAYED RELEASE;ORAL | 216247-001 | Jun 16, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dexcel | HEMADY | dexamethasone | TABLET;ORAL | 211379-001 | Oct 3, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Dexcel | DONEPEZIL HYDROCHLORIDE | donepezil hydrochloride | TABLET;ORAL | 203713-001 | Feb 19, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dexcel | HEMADY | dexamethasone | TABLET;ORAL | 211379-001 | Oct 3, 2019 | RX | Yes | Yes | 11,304,961 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Dexcel
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Dexcel Pharma | OMEPRAZOLE | omeprazole | TABLET, DELAYED RELEASE;ORAL | 022032-001 | Dec 4, 2007 | 9,023,391 | ⤷ Start Trial |
| Dexcel Pharma | PERIOCHIP | chlorhexidine gluconate | TABLET;DENTAL | 020774-001 | May 15, 1998 | 5,023,082 | ⤷ Start Trial |
| Dexcel Pharma | PERIOCHIP | chlorhexidine gluconate | TABLET;DENTAL | 020774-001 | May 15, 1998 | 5,002,769 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for DEXCEL drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
International Patents for Dexcel Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2017216789 | ⤷ Start Trial |
| European Patent Office | 3932396 | ⤷ Start Trial |
| Israel | 255048 | ⤷ Start Trial |
| European Patent Office | 3288556 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2016174664 | ⤷ Start Trial |
| European Patent Office | 3471708 | ⤷ Start Trial |
| Israel | 255048 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Dexcel Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1830843 | 15C0046 | France | ⤷ Start Trial | PRODUCT NAME: NINTEDANIB,SES TAUTOMERES ET LEURS MELANGES AINSI QUE LES SELS PHYSIOLOGIQUEMENT ACCEPTABLES DE NINTEDANIB ET PLUS PARTICULIEREMENT L'ESILATE; REGISTRATION NO/DATE: EU/1/14/979 20150119 |
| 0328535 | 96C0021 | Belgium | ⤷ Start Trial | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
| 1830843 | 92762 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: NINTEDANIB , OU UN TAUTOMERE, LES MELANGES OBTENUS OU UN DESES SELS, EN PARTICULIER NINTEDANIB ESILATE. FIRST REGISTRATION: 20150119 |
| 1666481 | 2017/036 | Ireland | ⤷ Start Trial | PRODUCT NAME: TOFACITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE CITRATE SALT; REGISTRATION NO/DATE: EU/1/17/1178/001 EU/1/17/1178/004 20170322 |
| 1666481 | CR 2017 00035 | Denmark | ⤷ Start Trial | PRODUCT NAME: TOFACITINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HERUNDER CITRAT-SALTET; REG. NO/DATE: EU/1/17/1178/001-003 20170324 |
| 1666481 | 37/2017 | Austria | ⤷ Start Trial | PRODUCT NAME: TOFACITINIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES, EINSCHLIESSLICH DES CITRATS; REGISTRATION NO/DATE: EU/1/17/1178 (MITTEILUNG) 20170324 |
| 1224170 | 2015/017 | Ireland | ⤷ Start Trial | PRODUCT NAME: VARGATEF-NINTEDANIB, THE TAUTOMERS AND THE PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
